Upstream stimulation — keeping the axis running

What actually decides this outcome, in order of size

This pathway has exactly one entry condition, and the page names it in passing without saying how to check it. Ranked by how much of the outcome each one owns:

1. Whether the testis can respond, which is a single pair of numbers. A raised luteinizing hormone with a low testosterone means the pituitary is already shouting and the gonad is not answering. Every compound on this page shouts louder. None of them makes a Leydig cell that is not there, and evaluation guidance puts the gonadotropins in the workup for exactly this reason Bhasin 2018.
2. Whether something is suppressing the pituitary that is not on this shelf. Prolactin, chronic opioid exposure, systemic illness and a high estrogen signal all reduce gonadotropin output through separate routes, and all four are more common than the population these compounds were trialed in. Suppression of spermatogenesis by exogenous testosterone is its own well-described version of the same problem Desai 2022.
3. Which isomer, for the oldest drug here. Clomiphene citrate is a mixture, and serum levels of enclomiphene and zuclomiphene have been measured separately in men Helo 2017; single-dose pharmacokinetics of the mixture were characterized decades ago Mikkelson 1986. Zuclomiphene has the long half-life and accumulates, which is the pharmacokinetic explanation for why some men feel poorly on the mixed product and better on the isolated trans-isomer.
4. Where in the axis the intervention acts, because that determines what it preserves. A selective estrogen receptor modulator works at the pituitary and needs a functioning one; enclomiphene raised testosterone while gonadotropins rose Wiehle 2013 Wiehle 2014. Human chorionic gonadotropin acts at the Leydig cell directly, and low-dose hCG maintained intratesticular testosterone in normal men during testosterone-induced gonadotropin suppression Coviello 2005. Those are not interchangeable.
5. The products, last, and the natural half of the shelf has been audited as a class. A systematic review asked whether marketed testosterone boosters raise serum total testosterone and found the ingredient claims largely unsupported Morgado 2023. The exception with a randomized human trial on this specific list is purified shilajit, examined for spermatogenic activity in oligospermia Biswas 2010.

The order to run these in, and what has to be true first

Find out whether the axis is intact, remove what is suppressing it, then stimulate. Stimulating first is how somebody spends six months on a SERM with a luteinizing hormone that was already at the top of the range.

1. LH & FSH with Total Testosterone and SHBG (Sex Hormone-Binding Globulin), morning and fasted, on two occasions. Two because a single low testosterone is not a diagnosis and the evaluation guidance asks for repetition Bhasin 2018. The gonadotropins are what tell you whether this page applies at all, and they cost almost nothing next to the compounds.
2. Prolactin and Estradiol, Sensitive (LC/MS-MS) on the same draw. Prolactin suppresses gonadotropin-releasing hormone pulses, and a high estrogen signal closes the same negative feedback loop the SERMs on this page exist to open. The sensitive estradiol assay is the correct one in men because the standard assay is optimized for higher concentrations.
3. A semen analysis if fertility is the reason you are here. It is not a blood test, it is the only direct measure of the outcome, and it is the endpoint that separates this page from SHBG & free testosterone. Two samples, because between-sample variation is large.
4. Enclomiphene first among the pharmacological options. It restored testosterone while preserving gonadotropin output in men Wiehle 2013 Wiehle 2014, its safety and efficacy have been systematically reviewed Saffati 2024, and a more recent review compares it against the mixed isomer for the same indication Hohl 2025. It is the version of this drug with the fewest moving parts.
5. Clomiphene is the same mechanism at a lower price and with a longer tail. Oral clomiphene citrate stimulates endogenous testosterone production Kaminetsky 2013, and the zuclomiphene fraction is what accumulates Helo 2017. Visual disturbance secondary to clomiphene is a documented adverse effect and it is the one that should stop the drug rather than be tolerated Purvin 1995.
6. HCG when the target is the testis rather than the pituitary. Low-dose human chorionic gonadotropin maintained intratesticular testosterone during gonadotropin suppression Coviello 2005, which is the mechanistic basis for using it to keep testicular function and fertility on exogenous testosterone Desai 2022. Tamoxifen is the other SERM and is genuinely first-line in gynecomastia.
7. Gonadorelin has to be pulsed and that is not a preference. Pulsatile gonadotropin-releasing hormone is a physiologic paradigm with defined clinical applications Filicori 2023, and continuous exposure downregulates the receptor and suppresses the axis. Triptorelin produces a flare before profound downregulation and Cetrorelix is a pure antagonist; both are on this page so the class is understood, not because they belong in this protocol.
8. Kisspeptin is the most interesting lever here and the least protocolized. Continuous infusion dynamically modulates luteinizing hormone secretion in healthy men Naveed 2026, and chronic subcutaneous kisspeptin-10 stimulated gonadotropin secretion for 12 days Yeung 2026. Twelve days is the longest human exposure on record, so any claim about a maintenance protocol beyond that is extrapolation from a 12-day result and is not evidence.
9. Tongkat Ali and Shilajit are the two botanicals with randomized data, and the rest of the shelf is the audited category. Purified shilajit was trialed for spermatogenic activity in oligospermia Biswas 2010. Fadogia Agrestis, Turkesterone, Cistanche, Tribulus Terrestris and Testosterone Support sit inside a category the systematic review found largely unsupported Morgado 2023.

What gets bought for this that cannot move it

The whole pathway fails structurally in primary testicular failure, and one blood test decides it. If luteinizing hormone is already high, the signal is arriving and the gonad is not converting it. A SERM that raises LH further raises a signal that is already maximal. This is not a subtle point and it is the reason the gonadotropins belong in the initial evaluation rather than after a failed trial Bhasin 2018.

Tribulus Terrestris is the item here whose sales most exceed its results. It sits inside the class the systematic review of testosterone boosters examined and found unsupported for raising serum total testosterone Morgado 2023. Some trials do report improved sexual function scores, which is a different endpoint from the one this page is named after, and conflating the two is how the product survives its own literature.

Clomiphene carries a specific tail that the price advantage hides. The zuclomiphene fraction accumulates Helo 2017, so stopping the drug does not stop the exposure for weeks, and a washout before a follow-up blood test has to be measured in weeks rather than days. Visual symptoms are a described adverse effect and are a reason to stop rather than to persist Purvin 1995.

And if the situation is different, this is the wrong page. Anybody currently taking exogenous testosterone is on a different problem and belongs at Recovering the axis — post-cycle and post-TRT. A normal total testosterone with a high binding globulin belongs at SHBG & free testosterone. An estrogen complaint belongs at Aromatase & estrogen management, and hair or prostate concerns belong at 5-alpha-reductase, DHT & the hair trade-off.

How you would know it was working, on a real read-out and a real timescale

The prediction on this page is sequential, which makes it unusually easy to falsify. A pituitary-level agent should raise LH & FSH first and Total Testosterone second. If testosterone rises while the gonadotropins fall, the source is exogenous rather than endogenous, and that is the opposite of what this pathway claims to be doing.

• LH & FSH with Total Testosterone at baseline and at 4 to 6 weeks. Four to six weeks because a SERM acts on pituitary feedback within days and the downstream testicular response needs a few weeks to express itself Wiehle 2014. Same morning window both times, because the diurnal amplitude of testosterone exceeds most treatment effects.
• Estradiol, Sensitive (LC/MS-MS) on the same draws. Blocking estrogen feedback raises testosterone, and aromatization raises estradiol with it, so the estrogen number is the expected consequence rather than a complication. Reading a rise as a reason to add an aromatase inhibitor is how people crash a working axis.
• SHBG (Sex Hormone-Binding Globulin) with the Comprehensive Metabolic Panel (CMP) at baseline and 12 weeks. SERMs have hepatic effects and SHBG is one of the proteins that reports them, so a rising binding globulin can eat the free-fraction gain that the rising total was supposed to deliver.
• Complete Blood Count (CBC) with Differential at 12 weeks. A meaningful rise in endogenous testosterone raises hematocrit, and that is a real and monitorable consequence rather than a theoretical one. It is also the marker that separates a genuine androgen effect from a subjective one.
• A repeat semen analysis at 3 months if fertility is the endpoint, and the window has a hard biological reason. One cycle of spermatogenesis plus epididymal transit takes roughly three months, so a sample taken at 6 weeks is reporting cells that were already committed before the drug started. Judging fertility earlier than that is measuring the wrong cohort of cells.

What will fool you. Testosterone has a diurnal rhythm and falls with acute illness, and one week of restricted sleep lowers daytime levels in healthy young men Leproult 2011, so a follow-up drawn after a bad week understates a real effect. Zuclomiphene accumulates and clears slowly Helo 2017, so a post-treatment baseline taken days after stopping the mixed isomer is still on the drug. hCG raises testosterone directly, so it cannot be used to prove that the pituitary recovered Coviello 2005. And a rising subjective score with flat gonadotropins is the pattern produced by a booster product that the systematic review already predicted would not move the hormone Morgado 2023.

Sources read for these sections

• Wiehle R, Cunningham GR, Pitteloud N, Wike J, Hsu K, Fontenot GK, Rosner M, Dwyer A, Podolski J. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.. BJU Int 2013 · PMID 23875626
• Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (ZA-203, NCT01270841).. Fertil Steril 2014 · PMID 25044085
• Helo S, Mahon J, Ellen J, Wiehle R, Fontenot G, Hsu K, Feustel P, Welliver C, McCullough A. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment.. BJU Int 2017 · PMID 27511863
• Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, Sande-Lee SV, Ronsoni MF. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.. Arch Endocrinol Metab 2025 · PMID 41066380
• Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.. Transl Androl Urol 2024 · PMID 39434750
• Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel.. J Sex Med 2013 · PMID 23530575
• Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers.. Fertil Steril 1986 · PMID 3091405
• Purvin VA. Visual disturbance secondary to clomiphene citrate.. Arch Ophthalmol 1995 · PMID 7710399
• Coviello AD, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology and Metabolism 2005 · PMID 15713727
• Desai A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology 2022 · PMID 35783920
• Filicori M. Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm. F&S Reports 2023 · PMID 37223766
• Yeung AC. Chronic Subcutaneous Kisspeptin-10 Stimulates Gonadotropin Secretion for 12 Days in Healthy Men. European Journal of Endocrinology 2026 · PMID 42549827
• Naveed A. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens) 2026 · PMID 42230485
• Morgado A. Do “testosterone boosters” really increase serum total testosterone? A systematic review. International Journal of Impotence Research 2023;36(4):348-354 · PMID 37697053
• Biswas TK, et al. Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia 2010 · PMID 20078516
• Bhasin S. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2018;103(5):1715-1744 · PMID 29562364
• Leproult R. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA 2011;305(21):2173-74 · PMID 21632481